Percutaneous Intradiscal Electrothermal Annuloplasty, Percutaneous Intradiscal Radiofrequency Annuloplasty and Biacuplasty

**Number** 7.01.72*
**Effective Date** April 1, 2017
**Revision Date(s)** 03/14/17; 05/10/16; 09/08/15; 09/08/14; 09/09/13; 09/11/12; 09/13/11; 10/12/10; 06/09/09; 05/13/08; 12/12/06; 03/14/06; 09/15/04
**Replaces** 7.01.514

*Medicare has a policy

**Policy**

Percutaneous annuloplasty (e.g., intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, or intradiscal biacuplasty) for the treatment of chronic discogenic back pain is considered investigational.

**Related Policies**

- **7.01.18** Automated Percutaneous and Endoscopic Discectomy
- **7.01.93** Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty)

**Policy Guidelines**

**Coding**

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22526</td>
<td>Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level</td>
</tr>
<tr>
<td>22527</td>
<td>1 or more additional levels (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

**Description**
Electrothermal intradiscal annuloplasty therapies use radiofrequency energy sources to treat discogenic low back pain arising from annular tears. These annuloplasty techniques are designed to decrease pain arising from the annulus by thermocoagulating nerves in the disc and tightening of annular tissue.

**Background**

Discogenic low back pain is a common, multifactorial pain syndrome that involves low back pain without radicular symptoms findings, in conjunction with radiologically confirmed degenerative disc disease. Typical treatment includes conservative therapy with physical therapy and medication management, with potential for surgical decompression in more severe cases.

A number of electrothermal intradiscal procedures have been introduced to treat discogenic low back pain; they rely on various probe designs to introduce radiofrequency (RF) energy into the disc. It has been proposed that heat-induced denaturation of collagen fibers in the annular lamellae may stabilize the disc and potentially seal annular fissures and that pain reduction may occur through the thermal coagulation of nociceptors in the outer annulus.

Some of the electrothermal intradiscal procedures are briefly described.

With the intradiscal electrothermal annuloplasty (IDEA) procedure, a navigable catheter with an embedded thermal resistive coil is inserted posterolaterally into the disc annulus or nucleus. Using indirect RF energy, electrothermal heat is generated within the thermal resistive coil at a temperature of 90°C; the disc material is heated for up to 20 minutes. Proposed advantages of indirect electrothermal delivery of RF energy with IDEA include precise temperature feedback and control, and the ability to provide electrothermocoagulation to a broader tissue segment than would be allowed with a direct RF needle.

Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) uses direct application of RF energy. With PIRFT, the RF probe is placed into the center of the disc, and the device is activated for only 90 seconds at a temperature of 70°C. The procedure is not designed to coagulate, burn, or ablate tissue. The Radionics RF Disc Catheter System has been specifically designed for this purpose.

Intradiscal biacuplasty involves use of 2 cooled RF electrodes placed on the posterolateral sides of the intervertebral annulus fibrosus. It is believed that by cooling the probes a larger area may be treated than could occur with a regular needle probe.

Annuloplasty using a laser-assisted spinal endoscopy kit to coagulate the disc granulation tissue (percutaneous endoscopic laser annuloplasty) has also been described.

**Regulatory Status**

A variety of radiofrequency (RF) coagulation devices are cleared for marketing by the U.S. Food and Drug Administration (FDA), some of which are designed for disc nucleotomy. In 2002, the Oratec Nucleotomy Catheter (ORATEC Interventions, Menlo Park, CA, acquired by Smith & Nephew in 2002) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The predicate device was the SpineCATH® Intradiscal Catheter, which received FDA clearance for marketing in 1999. Radionics (a division of Tyco Healthcare group) RF (Radiofrequency) Disc Catheter System received marketing clearance through FDA's 510(k) process in 2000. FDA product code: GEI.

The Baylis Pain Management Cooled Probe received marketing clearance through FDA's 510(k) process in 2005. It is intended for use "in conjunction with the Radio Frequency Generator to create radiofrequency lesions in nervous tissue." FDA product code: GXI.

**Note:** This policy does not address DISC Nucleoplasty™, a technique based on a device offered by ArthroCare (Austin, TX). With the ArthroCare system, a bipolar RF device is used to provide lower energy treatment (Coblation®) to the intervertebral disc, which is designed to provide tissue removal with minimal thermal damage to collateral tissue. DISC Nucleoplasty is closer in concept to a laser discectomy in that tissue is removed or ablated in an effort to provide decompression of a bulging disc. DISC Nucleoplasty and laser discectomy are considered separately in another policy. (See Related Policies)
Scope

Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

Benefit Application

Intradiscal electrothermal therapy may be performed in the setting of a pain management clinic.

Rationale

This policy was originally based in part on TEC Assessments from 2002 and 2003, with periodic updates of the literature using the MEDLINE database.(1, 2) The most recent literature review was performed through November 1, 2016.

As with any therapy for pain, a placebo effect is anticipated, and thus randomized placebo-controlled trials are necessary to investigate the extent of the placebo effect and to determine whether any improvement with annuloplasty exceeds that associated with a placebo. Therefore, evidence reviewed for this policy focuses on randomized controlled trials (RCTs).

Intradiscal Electrothermal Procedures

A 2013 review of the evidence for American Society of Interventional Pain Physicians guidelines found limited to fair evidence for intradiscal electrothermal annuloplasty (IDET™) and biacuplasty and limited evidence for percutaneous intradiscal radiofrequency thermocoagulation (PIRFT). (3) Based on the evidence of 1 positive randomized trial (Pauza et al.) and 4 positive observational studies that met inclusion criteria, and negative evidence from another randomized trial that they considered to be flawed (Freeman et al) and an observational study, the review concluded that evidence for IDET™ is fair. They identified one randomized trial by Kapural for biacuplasty that showed modest benefits. The single study evaluating PIRFT (Kvarstein et al) (sections that follow further describe all of these studies) showed no benefit from the procedure.

Intradiscal Electrothermal Annuloplasty

Pauza et al (2004) published the results of an RCT(4) evaluating IDEA (referred to as intradiscal electrothermal therapy [IDET] in this report) in patients with discogenic low back pain, which was the focus of discussion in the 2003 TEC Assessment. The trial included 64 patients with low back pain of more than 6 months in duration who were randomized to IDEA or to sham procedure. Visual analog scale (VAS) score for pain was reduced by an average of 2.4 cm in the IDEA group compared with 1.1 cm in the sham group, a significant difference between groups (p=0.045). The mean change in the Oswestry Disability Index (ODI) score was also significantly greater for the IDEA group than for the sham group.

The improvement on the 36-Item Short-Form Health Survey (SF-36) bodily pain subscale score was slightly higher for the IDEA group. The trial also reported the percent change in VAS score more than 2.0 cm, which is greater than the minimally clinically significant improvement of 1.8 to 1.9. When the VAS score was dichotomized in this way, a relative risk of 1.5 was observed with a 95% confidence interval of 0.82 to 2.74. While this single-center trial was well-designed with respect to randomization, clear description of intervention, and use of valid and reliable outcomes measures, it does not permit conclusions about the relative effects of IDEA and placebo, and it is unclear whether IDEA achieves clinically and statistically significant improvements in measures of pain, disability, and quality of life.
In 2005, Freeman et al reported on an industry-sponsored, double-blinded, sham-controlled randomized trial evaluating IDEA (referred to as IDET in this report) in patients with chronic discogenic low back pain, marked functional disability, magnetic resonance imaging evidence of degenerative disc disease, and failure of conservative management. (5) Both the active IDEA and sham groups had an intradiscal catheter that was navigated to cover at least 75% of the posterior annulus. Planned enrollment based on power analysis was for 75 patients; however, the trial was stopped early due to slower than expected recruitment after 57 patients (38 IDEA, 19 placebo) had been enrolled. Follow-up was for 6 months, and the outcome measure was successful treatment response, as defined by all of the following: 1) no neurologic deficit; 2) an increase on the Low Back Outcome Score (LBOS) of at least 7 points; and 3) improvements in the SF-36 physical functioning and bodily pain subscales scores of at least 1 SD. No subject in either group achieved a successful treatment response. Outcomes were similar between the IDET and sham groups on the LBOS (38.31 vs 37.45), ODI score (39.77 vs 41.58), SF-36 subscales score (35.10 vs 30.40), the Zung Depression Index score (41.39 vs 40.82), and the Modified Somatic Perception Questionnaire (8.67 vs 8.6), respectively. None of the subgroup analyses showed statistically or clinically significant differences in study outcomes. No serious adverse events were reported in either group.

Section Summary

The 2 RCTs on IDEA reported conflicting results, with 1 finding a benefit for IDEA and the other no benefit. The most recent RCT identified was from 2005. No recent literature on IDEA has been identified.

Percutaneous Intradiscal Radiofrequency Annuloplasty

There is relatively minimal published data on PIRFT. In 2001, Barendse et al. reported on a double-blind trial that randomly assigned 28 patients with chronic low back pain to undergo PIRFT or to a sham control group. (6) The primary outcome was the percentage of success at 8 weeks, as measured by changes in pain level, impairment, ODI, and analgesics taken. At the end of 8 weeks, there were 2 treatment successes in the sham group compared with one in the treatment group. The authors concluded that PIRFT was no better than the placebo in reducing pain and disability.

In 2009, Kvarstein et al. published 12-month follow-up from an RCT of intra-annular RF thermal disc therapy using the discTRODE™ probe. (7) Recruitment was discontinued when blinded interim analysis of the first 20 patients showed no trend toward overall effect or difference in pain intensity between active and sham treatment at 6 months. At 12 months, there was a reduction from baseline pain but no significant difference between the 2 groups. Two patients from each group reported an increase in pain.

Section Summary

Two sham-controlled RCTs showed no evidence of a benefit with PIRFT. One study found that only 1 of 14 patients was considered a treatment success. The other was terminated after blinded interim analysis showed no trend to benefit compared to sham.

Intradiscal Radiofrequency Biacuplasy

Kapural, Desai, and colleagues have published several studies on use of transdiscal radiofrequency annuloplasty using 2 transdiscal probes (biacuplasy) in patients with discogenic lower back pain, including a 2013 industry-sponsored, phase 1, double-blind RCT and a 2016 RCT. (8-11)

In the phase 1 RCT by Kapural et al (2013), of 1894 patients screened, 1771 (94%) did not meet inclusion criteria. (8) Sixty-four subjects consented and were enrolled in the study. Outcome measures were the SF-36 physical functioning subscale (0-100), a numeric rating scale (NRS) for pain (0-10), and the ODI (0-100). There were no significant differences between the groups at 1 month or 3 months. At 6 months, the biacuplasy group showed a significantly greater change from baseline for the SF-36 (15.0 vs 2.63), NRS (-2.19 vs -0.64), and ODI (-7.43 vs 0.53) scores. Mean SF-36 and NRS scores were considered to be clinically significant, but mean ODI scores did not achieve the minimally important difference of 10 points. With clinical success defined post hoc as a 15-point increase in physical function together with a greater-than-2-point decrease in pain, 30% of biacuplasy patients and 3% of sham-treated patients were considered successful. There was no significant difference in opioid use between groups.
In 2015, Kapural et al reported unblinded 12-month follow-up from this phase 1 trial.(11) Improvements continued through 12 months, with a change from baseline to posttreatment of 47.0 to 68.9 (of 100) on the SF-36 physical functioning subscale (p<0.01) and 7.1 to 4.4 (of 10) on the NRS (p<0.01). Although the change in NRS score was statistically significant, the magnitude of the decrease was modest and a final NRS score (4.4) remained high. The change in ODI score (from 40.37 at baseline to 32.44 at 12 months) was also modest (p=0.05). Opioid usage did not decrease significantly (53.47 mg at baseline to 34.07 mg at follow-up, p=0.23).

In the 2016 RCT by Desai et al, 63 patients with lumbar discogenic pain diagnosed by provocation discography were randomized to intradiscal biacuplasty plus conservative medical management (n=29) or medical management alone (n=34). Another 234 patients were scheduled for diagnostic discography but did not meet inclusion criteria. The primary outcome (the mean reduction in VAS score for pain at 6 months) was significantly greater in the biacuplasty group (-2.4) than in the medical management group (-0.56; p=0.02). The secondary outcomes were not statistically significant, which included the proportion of responders, defined as a 2-point or 30% decrease in VAS scores, which was achieved in 50% of the biacuplasty group compared to 18% of controls (p=0.073). Investigators did not report whether the trial was adequately powered. Another limitation of this industry-sponsored trial was the lack of a sham control and patient blinding, which could contribute to a placebo effect in the subjective pain outcomes.

Of the 29 patients originally randomized to intradiscal biacuplasty, 22 (76%) were available for 12-month follow-up.(10) Mean 12-month change in VAS score was -2.2 (from 6.7 at baseline to 4.4 at 12 months, p=0.001). After 6 months, patients randomized to medical management were allowed to receive intradiscal biacuplasty and were followed for another 6 months; 25 of 34 patients crossed over. VAS score improved from 7.0 to 4.7 (p<0.001) in the crossover group, and 55% were considered to be responders.

**Section Summary**
Two industry-sponsored RCTs have assessed use of biacuplasty to treat chronic low back pain. In 1 report, only 6% of subjects screened met the strict inclusion and exclusion criteria for the study. Significant differences in outcomes were observed at 6 months, but not at 1 month or 3 months, and the definition of successful treatment appears to have been post hoc. In the second multicenter RCT, 63 patients met inclusion criteria, which included a positive result on provocation discography. There was a significant effect of treatment for the primary outcome measure, but not the secondary outcome measures. This trial was not sham-controlled, and it was not reported if it was adequately powered. Additional sham-controlled trials in a broader population of patients are needed to determine the effect of this treatment with greater certainty.

**Ongoing and Unpublished Clinical Trials**
A search of ClinicalTrials.gov in December 2016 did not identify any ongoing or unpublished trials that would likely influence this review.

**Summary of Evidence**
For individuals who have discogenic back pain who receive intradiscal thermal annuloplasty, radiofrequency annuloplasty, or biacuplasty, the evidence includes a small number of randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The 2 RCTs on intradiscal electrothermal annuloplasty have conflicting results, with 1 reporting benefit for intradiscal electrothermal annuloplasty and the other reporting no benefit. There is a lack of evidence to support a role for radiofrequency annuloplasty with either a single or a double (bicuplasty) probe. One sham-controlled RCT on biacuplasty has suggested that this procedure may provide modest benefit in highly select patients; confirmation of these results in a broader population is needed. Further study in a sham-controlled trial with a representative population of patients is needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Practice Guidelines and Position Statements**

**American Society of Interventional Pain Physicians**
A 2013 review of the evidence for American Society of Interventional Pain Physicians guidelines found limited -to
-fair evidence for IDET™ and biacuplasty and limited evidence for percutaneous intradiscal radiofrequency thermocoagulation (PIRFT). This updates 2007 guidelines that concluded that the evidence was moderate for management of chronic discogenic low back pain with IDET™. (12) Complications include catheter breakage, nerve root injuries, post-IDET™ disc herniation, cauda equina syndrome, infection, epidural abscess, and spinal cord damage. The evidence for PIRFT was reported to be limited, with complications similar to IDET™. (12)

**National Institute for Health and Clinical Excellence**

The U.K.'s National Institute for Health and Clinical Excellence (NICE) guidance, published in 2004, indicates that the current evidence on safety and efficacy of PIRFT for lower back pain does not appear adequate to support its use. (13)

The NICE guidance on electrothermal annuloplasty was updated in 2009. (14) NICE considers evidence on the safety and efficacy of percutaneous intradiscal electrothermal therapy for low back pain to be inconsistent. NICE recommends that this procedure only be used with special arrangements for clinical governance, consent, and audit or research.

**U.S. Preventative Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

The Centers for Medicare and Medicaid Services has determined that thermal intradiscal procedures, including IDET™ and PIRFT, are not reasonable and necessary for the treatment of low back pain. Therefore, thermal intradiscal procedures, which include procedures that employ the use of a radiofrequency energy source or electrothermal energy to apply or create heat and/or disruption within the disc for the treatment of low back pain, are noncovered. (15)

**References**

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intradiscal electrothermal therapy for chronic low back pain. TEC Assessments Apr 2002;Volume 17:Tab 11. PMID 11010675

Appendix

N/A

History

<table>
<thead>
<tr>
<th>Date</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/11/04</td>
<td>Add to Surgery Section - New Policy, replaces PR.7.01.514—effective September 15, 2004</td>
</tr>
<tr>
<td>03/14/06</td>
<td>Replace Policy - Policy updated with literature search; no change in policy statement.</td>
</tr>
<tr>
<td>06/09/06</td>
<td>Disclaimer and Scope update - No further changes.</td>
</tr>
<tr>
<td>12/12/06</td>
<td>Replace Policy - Policy updated with literature review; references added; no change in policy statement.</td>
</tr>
<tr>
<td>05/13/08</td>
<td>Replace Policy - Policy updated with literature search. Policy statement revised to include biacuplasty as investigational. Title updated to add “annuloplasty” and deleted “thermocoagulation”. References added.</td>
</tr>
<tr>
<td>07/08/08</td>
<td>Code Update - 62310 and 62311 added, deleted 62288, no other changes.</td>
</tr>
<tr>
<td>10/14/08</td>
<td>Cross Reference Update - No other changes.</td>
</tr>
<tr>
<td>06/09/09</td>
<td>Replace Policy - Policy updated with literature search; no change in policy statement. References added.</td>
</tr>
<tr>
<td>10/12/10</td>
<td>Replace Policy - Policy updated with literature review through June 2010. References have been added and reordered; the policy statement remains unchanged.</td>
</tr>
<tr>
<td>04/08/11</td>
<td>Codes Updates - Deleted codes 0062T and 0063T removed from policy.</td>
</tr>
<tr>
<td>09/15/11</td>
<td>Replace Policy – Policy updated with literature review through May 2011; reference 13 added and references reordered; policy statement unchanged.</td>
</tr>
<tr>
<td>04/17/12</td>
<td>Related Policies updated; the title of 7.01.18 now includes endoscopic discectomy.</td>
</tr>
<tr>
<td>09/11/12</td>
<td>Replace policy. Rationale section revised based on literature search through May 2012. Reference 4 added and other references renumbered. Policy statement unchanged.</td>
</tr>
<tr>
<td>09/08/15</td>
<td>Annual Review. Policy updated with literature review through June 10, 2015; reference 17 added. Policy statement unchanged. Removed CPT codes 62290-92, 62310-11, 64690, 72285 and 72295; these are not utilized for review and do not directly pertain to the policy.</td>
</tr>
<tr>
<td>05/10/16</td>
<td>Annual Review. No changes to policy statements. Literature review through April 18, 2016.</td>
</tr>
</tbody>
</table>
Annual review. Policy updated with literature review through November 1, 2016; references 9-10 added; reference 14 updated; some references removed. Title changed to "Percutaneous intradiscal electrothermal annuloplasty, radiofrequency annuloplasty, and biacuplasty." Policy statement terminology revised to reflect the changes in the title but the intent is unchanged.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
©2017 Premera All Rights Reserved.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

中文 (Chinese):

本通知有重要的訊息。本通知可能有關於您透過Premera Blue Cross提交的申請或保險的重要訊息。本通知可能有重要日期。您可能需要在截止日期之前採取行動，以保留您的健康保險或費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357).

Oromo (Cushite):


Français (French):


Kreyòl ayisyen (Creole):

Avi sila a gen Enfòmasyon Empôt Anadann. Avi sila a kapab genyen enfòmasyon empôton konsénan aplikasyon w lan oswa konsekan kouvèti a amin lan atravé Premera Blue Cross. Kapab genyen dat ki enpôtan nan avsila a. Ou ka gen pou pran kôk aksyon avan sêten dat limit pou ka kote kouvèti a amin lan sante w la oswa pou yo ka ede w avèk despars yo. Se dwa w pou resewwa enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou peye pou sa. Rate nan 800-722-1471 (TTY: 800-842-5357).

Deutsche (German):


Hmoob (Hmong):


Iloko (Ilocano):

Daytoy a Pakdaa ket naglaon iti Napateg nga Impormasion. Daytoy a pakdaa mabalini nga adda ket naglaon iti napateg nga impormasion maiyanggo epikalapuyonon nga coverage babenan iti Premera Blue Cross. Daytoy ket mabalini dagiti importante a pelsa iti daytoy a pakdaar. Mabalini nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga adda aldaw tapno mapattalaindyo ti coverage ti salun-atyo nga tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong ti bukodyo a pagasasao nga awan ti bayadanyo. Tumawag ti numero nga 800-722-1471 (TTY: 800-842-5357).

Italiano (Italian):

Informação importante.
Este aviso poderá conter informações importantes acerca do seu pedido ou cobertura através de Premera Blue Cross. É possível que haja datas específicas para manter sua cobertura ou ajuda com custos. Ligue para 800-722-1471 (TTY: 800-842-5357) para obter assistência.

Română (Romanian):

Русский (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Español (Spanish):
Este aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

Тагалог (Tagalog):
Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon. Ang paunawa na ito ay naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa Premera Blue Cross. Es posible que haya fechas claves en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

ไทย (Thai):
ประกาศนี้มีข้อมูลสําคัญต่อสิทธิของคุณเกี่ยวกับการขอรับสิทธิประกันสุขภาพของคุณผ่าน Premera Blue Cross และมิใช่ข้อมูลที่มีอยู่ในเอกสารนี้ มีการติดต่อกับสำนักงานที่มีชื่อเรียกว่า สำนักงานประกันสุขภาพของ Premera Blue Cross และมิใช่ข้อมูลที่มีอยู่ในเอกสารนี้ มีการติดต่อกับสำนักงานที่มีชื่อเรียกว่า สำนักงานประกันสุขภาพของ Premera Blue Cross.

日本語 (Japanese):
この通知には重要な情報が含まれています。この通知には、Premera Blue Crossの申請または補償範囲に関する重要な情報が含まれている場合があります。この通知には記録されている情報が重要な場合をご確認ください。健康保険や有料サポートを維持するには、特定の期日までに行動を取らなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

한국어 (Korean):
본 통지서에는 중요한 정보가 들어 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross 복구를 위한 커버리지에 관한 정보를 포함하고 있을 수 있습니다. 귀하의 귀하가 간단히 제안된 커버리지를 계신 증가되거나 질문을 점검하기 위해서 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다. 귀하는 이러한 정보와 도움을 귀하의 언어에 비용 부담없이 얻을 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357)로 전화하십시오.

اللغة العربية (Arabic):
الThông báo هذا يحتوي على معلومات مهمة. قد يكون هناك مواعيد محددة على هذا الإشعار المتعلق بالطلب أو الدعم المالي. قد يكون من الضروري اتخاذ بعض الإجراءات قبل المواعيد المذكورة في الإشعار. يمكنك الحصول على معلومات ومساعدة مجاناً باللغة الخاصة بك. الرد على 800-722-1471 (TTY: 800-842-5357).

Српски (Serbian):
Данашња информација може да садржи важне информације. Да би се сетили о важним датумима за остваривање својих права, Барајте се да контактирајте са својом здравственом компанијом. Можете да добијете бесплатно информације на свој власни језику. Контактни број: 800-722-1471 (TTY: 800-842-5357).

Русский (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Український (Ukrainian):
Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страхувального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дозвоніться за номером телефону 800-722-1471 (TTY: 800-842-5357).

Tiếng Việt (Vietnamese):